In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 03 2021
05 03 2021
Historique:
received:
07
08
2020
accepted:
11
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Plasmodium falciparum malaria contributes to a significant global disease burden. Circumsporozoite protein (CSP), the most abundant sporozoite stage antigen, is a prime vaccine candidate. Inhibitory monoclonal antibodies (mAbs) against CSP map to either a short junctional sequence or the central (NPNA)
Identifiants
pubmed: 33674699
doi: 10.1038/s41598-021-84622-x
pii: 10.1038/s41598-021-84622-x
pmc: PMC7970865
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Protozoan
0
Malaria Vaccines
0
Protozoan Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
5318Références
World Health Organization. World Malaria Report (World Health Organization, 2019).
Julien, J. P. & Wardemann, H. Antibodies against Plasmodium falciparum malaria at the molecular level. Nat. Rev. Immunol. 19, 761–775. https://doi.org/10.1038/s41577-019-0209-5 (2019).
doi: 10.1038/s41577-019-0209-5
pubmed: 31462718
Coppi, A., Pinzon-Ortiz, C., Hutter, C. & Sinnis, P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J. Exp. Med. 201, 27–33. https://doi.org/10.1084/jem.20040989 (2005).
doi: 10.1084/jem.20040989
pubmed: 15630135
pmcid: 1995445
Plassmeyer, M. L. et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J. Biol. Chem. 284, 26951–26963 (2009).
doi: 10.1074/jbc.M109.013706
Doud, M. B. et al. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc. Natl. Acad. Sci. U.S.A. 109, 7817–7822. https://doi.org/10.1073/pnas.1205737109 (2012).
doi: 10.1073/pnas.1205737109
pubmed: 22547819
pmcid: 3356675
Coppi, A. et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 208, 341–356. https://doi.org/10.1084/jem.20101488 (2011).
doi: 10.1084/jem.20101488
pubmed: 21262960
pmcid: 3039851
Gordon, D. M. et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576–1585. https://doi.org/10.1093/infdis/171.6.1576 (1995).
doi: 10.1093/infdis/171.6.1576
pubmed: 7769295
Regules, J. A. et al. Fractional third and fourth dose of RTS, S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. J. Infect. Dis. 214, 762–771. https://doi.org/10.1093/infdis/jiw237 (2016).
doi: 10.1093/infdis/jiw237
pubmed: 27296848
Efficacy and safety of RTS. S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45. https://doi.org/10.1016/s0140-6736(15)60721-8 (2015).
doi: 10.1016/s0140-6736(15)60721-8
MESA Alliance. Large-Scale Implementation of the RTS, S Malaria Vaccine: Phase IV Trial (MESA Alliance, 2018).
Hickey, B. et al. IMRAS-A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents. PLoS ONE 15, e0233840–e0233840. https://doi.org/10.1371/journal.pone.0233840 (2020).
doi: 10.1371/journal.pone.0233840
pubmed: 32555601
pmcid: 7299375
Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Proc. Natl. Acad. Sci. 24, 408–416. https://doi.org/10.1038/nm.4512 (2018).
doi: 10.1038/nm.4512
Mordmüller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445–449. https://doi.org/10.1038/nature21060 (2017).
doi: 10.1038/nature21060
pubmed: 28199305
Scally, S. W. et al. Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. J. Exp. Med. 215, 63–75. https://doi.org/10.1084/jem.20170869 (2018).
doi: 10.1084/jem.20170869
pubmed: 29167197
pmcid: 5748854
Fisher, C. R. et al. T-dependent B cell responses to Plasmodium induce antibodies that form a high-avidity multivalent complex with the circumsporozoite protein. PLoS Pathog. 13, e1006469. https://doi.org/10.1371/journal.ppat.1006469 (2017).
doi: 10.1371/journal.ppat.1006469
pubmed: 28759640
pmcid: 5552345
Langowski, M. D. et al. Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. Proc. Natl. Acad. Sci. U. S. A. 117, 3114–3122. https://doi.org/10.1073/pnas.1911792117 (2020).
doi: 10.1073/pnas.1911792117
pubmed: 31988134
pmcid: 7022184
Macintyre, F. et al. Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria. Malar. J. 17, 402. https://doi.org/10.1186/s12936-018-2549-1 (2018).
doi: 10.1186/s12936-018-2549-1
pubmed: 30384848
pmcid: 6211409
Oyen, D. et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc. Natl. Acad. Sci. U. S. A. 114, E10438-e10445. https://doi.org/10.1073/pnas.1715812114 (2017).
doi: 10.1073/pnas.1715812114
pubmed: 29138320
pmcid: 5715787
Triller, G. et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity 47, 1197-1209.e1110. https://doi.org/10.1016/j.immuni.2017.11.007 (2017).
doi: 10.1016/j.immuni.2017.11.007
pubmed: 29195810
pmcid: 5738265
Imkeller, K. et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science 360, 1358–1362. https://doi.org/10.1126/science.aar5304 (2018).
doi: 10.1126/science.aar5304
pubmed: 29880723
pmcid: 6420115
Tan, J. & Sack, B. K. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401–407. https://doi.org/10.1038/nm.4513 (2018).
doi: 10.1038/nm.4513
pubmed: 29554084
pmcid: 5893353
Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med. https://doi.org/10.1038/s41591-020-0881-9 (2020).
doi: 10.1038/s41591-020-0881-9
pubmed: 32451496
Ghasparian, A., Moehle, K., Linden, A. & Robinson, J. A. Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. Chem. Commun. Camb. https://doi.org/10.1039/b510812h (2006).
doi: 10.1039/b510812h
pubmed: 16372096
Oyen, D. et al. Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Sci. Adv. 4, eaau8529. https://doi.org/10.1126/sciadv.aau8529 (2018).
doi: 10.1126/sciadv.aau8529
pubmed: 30324137
pmcid: 6179375
Murugan, R. et al. Clonal selection drives protective memory B cell responses in controlled human malaria infection. Sci. Immunol. 3, eaap8029. https://doi.org/10.1126/sciimmunol.aap8029 (2018).
doi: 10.1126/sciimmunol.aap8029
pubmed: 29453292
Behet, M. C. et al. Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar. J. 13, 136. https://doi.org/10.1186/1475-2875-13-136 (2014).
doi: 10.1186/1475-2875-13-136
pubmed: 24708526
pmcid: 4113136
Kaushansky, A., Rezakhani, N., Mann, H. & Kappe, S. H. Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites. Mol. Biochem. Parasitol. 183, 100–103. https://doi.org/10.1016/j.molbiopara.2012.01.006 (2012).
doi: 10.1016/j.molbiopara.2012.01.006
pubmed: 22342965
pmcid: 3307955
Sack, B. K. et al. Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice. NPJ Vaccin. 2, 27. https://doi.org/10.1038/s41541-017-0028-2 (2017).
doi: 10.1038/s41541-017-0028-2
March, S. et al. Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. Nat. Protoc. 10, 2027–2053. https://doi.org/10.1038/nprot.2015.128 (2015).
doi: 10.1038/nprot.2015.128
pubmed: 26584444
pmcid: 5867906
Zou, X., House, B. L., Zyzak, M. D., Richie, T. L. & Gerbasi, V. R. Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum. Malar. J. 12, 394. https://doi.org/10.1186/1475-2875-12-394 (2013).
doi: 10.1186/1475-2875-12-394
pubmed: 24191920
pmcid: 3831258
Vaughan, A. M. et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J. Clin. Invest. 122, 3618–3628. https://doi.org/10.1172/jci62684 (2012).
doi: 10.1172/jci62684
pubmed: 22996664
pmcid: 3461911
Oyen, D. et al. Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 16, e1008373. https://doi.org/10.1371/journal.ppat.1008373 (2020).
doi: 10.1371/journal.ppat.1008373
pubmed: 32150583
pmcid: 7082059
Dennison, S. M. et al. Qualified biolayer interferometry avidity measurements distinguish the heterogeneity of antibody interactions with Plasmodium falciparum circumsporozoite protein antigens. J. Immunol. 201, 1315–1326. https://doi.org/10.4049/jimmunol.1800323 (2018).
doi: 10.4049/jimmunol.1800323
pubmed: 30006374
pmcid: 6077849
Foote, J. & Eisen, H. N. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. U. S. A. 92, 1254–1256. https://doi.org/10.1073/pnas.92.5.1254 (1995).
doi: 10.1073/pnas.92.5.1254
pubmed: 7877964
pmcid: 42497
Pullen, G. R., Fitzgerald, M. G. & Hosking, C. S. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 86, 83–87. https://doi.org/10.1016/0022-1759(86)90268-1 (1986).
doi: 10.1016/0022-1759(86)90268-1
pubmed: 3944471
Khurana, S. et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 3, 85ra48. https://doi.org/10.1126/scitranslmed.3002336 (2011).
doi: 10.1126/scitranslmed.3002336
pubmed: 21632986
pmcid: 3501657
Gupta, S. et al. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. J. Virol. 89, 4158–4169. https://doi.org/10.1128/jvi.02904-14 (2015).
doi: 10.1128/jvi.02904-14
pubmed: 25631080
pmcid: 4442371
Richmond, J. F. L. et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 env antibody elicited by DNA priming and protein boosting. J. Virol. 72, 9092–9100. https://doi.org/10.1128/jvi.72.11.9092-9100.1998 (1998).
doi: 10.1128/jvi.72.11.9092-9100.1998
pubmed: 9765454
pmcid: 110326
Dutta, S. et al. Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1. Infect. Immun. 78, 661–671. https://doi.org/10.1128/iai.00866-09 (2010).
doi: 10.1128/iai.00866-09
pubmed: 19948834
Porter, M. D. et al. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clin. Vaccin. Immunol. 20, 803–810. https://doi.org/10.1128/cvi.00066-13 (2013).
doi: 10.1128/cvi.00066-13
Stewart, M. J. & Vanderberg, J. P. Malaria sporozoites release circumsporozoite protein from their apical end and translocate it along their surface. J. Protozool. 38, 411–421. https://doi.org/10.1111/j.1550-7408.1991.tb01379.x (1991).
doi: 10.1111/j.1550-7408.1991.tb01379.x
pubmed: 1787427
Vanderberg, J., Nussenzweig, R. & Most, H. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites. Mil. Med. 134, 1183–1190 (1969).
doi: 10.1093/milmed/134.9.1183
Collaborative Computational Project. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763. https://doi.org/10.1107/s0907444994003112 (1994).
doi: 10.1107/s0907444994003112
Lee, K. H., Xie, D., Freire, E. & Amzel, L. M. Estimation of changes in side chain configurational entropy in binding and folding: general methods and application to helix formation. Proteins 20, 68–84. https://doi.org/10.1002/prot.340200108 (1994).
doi: 10.1002/prot.340200108
pubmed: 7824524
Murphy, K. P., Xie, D., Garcia, K. C., Amzel, L. M. & Freire, E. Structural energetics of peptide recognition: angiotensin II/antibody binding. Proteins 15, 113–120. https://doi.org/10.1002/prot.340150203 (1993).
doi: 10.1002/prot.340150203
pubmed: 8441749
Pholcharee, T. et al. Diverse antibody responses to conserved structural motifs in Plasmodium falciparum circumsporozoite protein. J. Mol. Biol. 432, 1048–1063. https://doi.org/10.1016/j.jmb.2019.12.029 (2020).
doi: 10.1016/j.jmb.2019.12.029
pubmed: 31883801
pmcid: 7057269
James, L. C. & Tawfik, D. S. Structure and kinetics of a transient antibody binding intermediate reveal a kinetic discrimination mechanism in antigen recognition. Proc. Natl. Acad. Sci. U. S. A. 102, 12730–12735. https://doi.org/10.1073/pnas.0500909102 (2005).
doi: 10.1073/pnas.0500909102
pubmed: 16129832
pmcid: 1200256
Rini, J. M., Schulze-Gahmen, U. & Wilson, I. A. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science 255, 959–965. https://doi.org/10.1126/science.1546293 (1992).
doi: 10.1126/science.1546293
pubmed: 1546293
Keskin, O. Binding induced conformational changes of proteins correlate with their intrinsic fluctuations: a case study of antibodies. BMC Struct. Biol. 7, 31. https://doi.org/10.1186/1472-6807-7-31 (2007).
doi: 10.1186/1472-6807-7-31
pubmed: 17509130
pmcid: 1888692
Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med. 26, 1135–1145. https://doi.org/10.1038/s41591-020-0881-9 (2020).
doi: 10.1038/s41591-020-0881-9
pubmed: 32451496
Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733-744.e738. https://doi.org/10.1016/j.immuni.2020.08.014 (2020).
doi: 10.1016/j.immuni.2020.08.014
pubmed: 32946741
pmcid: 7572793
Gilson, P. R. & Crabb, B. S. Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites. Int. J. Parasitol. 39, 91–96. https://doi.org/10.1016/j.ijpara.2008.09.007 (2009).
doi: 10.1016/j.ijpara.2008.09.007
pubmed: 18952091
Yamauchi, L. M., Coppi, A., Snounou, G. & Sinnis, P. Plasmodium sporozoites trickle out of the injection site. Cell Microbiol. 9, 1215–1222. https://doi.org/10.1111/j.1462-5822.2006.00861.x (2007).
doi: 10.1111/j.1462-5822.2006.00861.x
pubmed: 17223931
pmcid: 1865575
Potocnjak, P., Yoshida, N., Nussenzweig, R. S. & Nussenzweig, V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151, 1504–1513. https://doi.org/10.1084/jem.151.6.1504 (1980).
doi: 10.1084/jem.151.6.1504
pubmed: 6991628
Davey, R. T. Jr. et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N. Engl. J. Med. 375, 1448–1456. https://doi.org/10.1056/NEJMoa1604330 (2016).
doi: 10.1056/NEJMoa1604330
pubmed: 27732819
The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531–537 (1998).
doi: 10.1542/peds.102.3.531
Flores-Garcia, Y. et al. Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar. J. 18, 426. https://doi.org/10.1186/s12936-019-3055-9 (2019).
doi: 10.1186/s12936-019-3055-9
pubmed: 31849326
pmcid: 6918627
Gaudinski, M. R. Trial to evaluate CIS43LS in healthy adults. Identifier NCT04206332 https://ClinicalTrials.gov/show/NCT04206332 (2020).
Resch, B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum. Vaccin. Immunother. 13, 2138–2149. https://doi.org/10.1080/21645515.2017.1337614 (2017).
doi: 10.1080/21645515.2017.1337614
pubmed: 28605249
pmcid: 5612471
Flores-Garcia, Y. et al. Antibody-mediated protection against Plasmodium sporozoites begins at the dermal inoculation site. mBio https://doi.org/10.1128/mBio.02194-18 (2018).
doi: 10.1128/mBio.02194-18
pubmed: 30459199
pmcid: 6247089
Winkel, B. M. F. et al. Quantification of wild-type and radiation attenuated Plasmodium falciparum sporozoite motility in human skin. Sci. Rep. 9, 13436. https://doi.org/10.1038/s41598-019-49895-3 (2019).
doi: 10.1038/s41598-019-49895-3
pubmed: 31530862
pmcid: 6748968
Steel, R. W. et al. An opsonic phagocytosis assay for Plasmodium falciparum sporozoites. Clin. Vacc. Immunol. CVI https://doi.org/10.1128/cvi.00445-16 (2017).
doi: 10.1128/cvi.00445-16
Kurtovic, L. et al. Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. BMC Med. 16, 61. https://doi.org/10.1186/s12916-018-1054-2 (2018).
doi: 10.1186/s12916-018-1054-2
pubmed: 29706136
pmcid: 5925837
Espinosa, D. A. et al. Proteolytic cleavage of the Plasmodium falciparum circumsporozoite protein is a target of protective antibodies. J. Infect. Dis. 212, 1111–1119. https://doi.org/10.1093/infdis/jiv154 (2015).
doi: 10.1093/infdis/jiv154
pubmed: 25762791
pmcid: 4559189
Manzoni, G. et al. Plasmodium P36 determines host cell receptor usage during sporozoite invasion. Elife https://doi.org/10.7554/eLife.25903 (2017).
doi: 10.7554/eLife.25903
pubmed: 28506360
pmcid: 5470872
Tewari, R., Spaccapelo, R., Bistoni, F., Holder, A. A. & Crisanti, A. Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J. Biol. Chem. 277, 47613–47618. https://doi.org/10.1074/jbc.M208453200 (2002).
doi: 10.1074/jbc.M208453200
pubmed: 12244064
Raghunandan, R. et al. Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein. Malar. J. 19, 113. https://doi.org/10.1186/s12936-020-03181-0 (2020).
doi: 10.1186/s12936-020-03181-0
pubmed: 32183833
pmcid: 7079517
Knepper, T. A., Duncan, E. H., Savransky, T. & Bergmann-Leitner, E. S. Novel ELISA method as exploratory tool to assess immunity induced by radiated attenuated sporozoites to decipher protective immunity. Malar. J. 16, 484. https://doi.org/10.1186/s12936-017-2129-9 (2017).
doi: 10.1186/s12936-017-2129-9
pubmed: 29187199
pmcid: 5707923
Srinivasan, B. Explicit treatment of non Michaelis-Menten and atypical kinetics in early drug discovery. ChemMedChem https://doi.org/10.1002/cmdc.202000791 (2020).
doi: 10.1002/cmdc.202000791
pubmed: 33231926